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Acute kidney injury (AKI) remains a very common 
occurrence in critically ill patients and is associated with 
decreased survival in severe sepsis [1]. Effective treat-
ment for these patients is mostly through treatment of 
the underlying pathology as well as supportive care with 
renal replacement therapy (RRT). Optimised pharmaco-
therapy is of heightened importance to ensure maximal 
outcomes for critically ill patients with AKI receiving 
RRT, although the pharmacokinetics of many drugs can 
change dramatically in these patients, making effective 
dosing a challenge.
The purpose of this paper is to describe the new devel-
opments in antibiotic dosing and pharmacokinetics in 
critically ill patients with AKI and receiving RRT.
The overwhelming body of recent literature aims to 
understand how to better dose these compounds in criti-
cally ill patients receiving different forms of RRT, with 
far more data being generated for continuous than for 
intermittent RRT. Little data is available in AKI without 
RRT. Very few data on other classes of drugs are available 
which is largely due to the fact that many have negligible 
RRT clearance because of high protein binding, hepatic 
clearance or large volumes of distribution (e.g. most anti-
convulsants), have dosing that is titrated to effect (e.g. 
analgesics and sedatives) or have readily available thera-
peutic drug monitoring (TDM).
Recent pharmacokinetic studies of antibiotics have 
moved away from a drug-based dosing approach, where 
each drug has a given dose regardless of type of RRT, 
to a strategy where the specific drug dose accounts for 
the modality of RRT (e.g. intermittent, prolonged or 
continuous convective and/or diffusive RRT) and the 
associated settings (e.g. blood or ultrafiltration flow rate, 
filter material and surface area).
Most of the studies continue to evaluate only phar-
macokinetic endpoints and include small cohorts which 
limits the generalizability of findings. On the other hand, 
some comparative studies have been useful to better elu-
cidate the effect of different approaches to RRT, includ-
ing different modalities (i.e. intermittent and prolonged 
intermittent RRT and CRRT). It is hoped that the forth-
coming SaMpling Antibiotics in Renal Replacement 
Therapy (SMARRT) study (ACTRN12613000241730), 
endorsed by the Australian and New Zealand Intensive 
Care Society Clinical Trials Group (ANZICS-CTG), 
will address many of these issues. Further to this, use 
of ex  vivo models of RRT are providing suitable doses 
for drugs to be subsequently tested in clinical pharma-
cokinetic studies [2]. Such models are very useful as the 
interaction between changing RRT modalities and set-
tings on drug clearance, as well as potentially significant 
drug adsorption to the RRT membrane, can be more 
accurately calculated without the complicating effects of 
biology.
Important knowledge has been generated recently that 
has aimed to quantify the effect of the dose and type of 
RRT used. Using a meta-review methodology of pub-
lished studies, Jamal et al. highlighted the importance of 
CRRT dose where they found that extracorporeal CRRT 
clearance was correlated with effluent flow rate for mero-
penem, piperacillin and vancomycin [3]. Another impor-
tant report came from the pharmacokinetic substudy 
[4], within the RENAL study [5], which was a multina-
tional randomised controlled trial (RCT) that compared 
the effect of two different continuous venovenous hae-
modiafiltration (CVVHDF) doses, 25 versus 40  mL/
kg/h, on patient survival. After controlling for filter age 
and downtime, the authors observed that meropenem, 
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piperacillin, vancomycin and ciprofloxacin clearance was 
always numerically higher with the 40  mL/kg/h cohort, 
although the difference was only significant for vanco-
mycin (22% higher clearance in the 40  mL/kg/h group, 
p < 0.01). However, the dramatic variability in drug con-
centrations led the authors to conclude that singular 
dose recommendations were not possible and that TDM 
was the only way to ensure consistently effective doses. 
Indeed TDM is likely to be more valuable in RRT than 
in other scenarios because of dramatic pharmacokinetic 
variability, even whilst acknowledging the challenges of 
establishing TDM for some drugs like colistin.
It is important to note that suggestions that dosing rec-
ommendations for singular creatinine clearance can be 
assumed to be acceptable for RRT dosing (e.g. 30  mL/
min) are also unfounded as some drugs such as flucona-
zole and colistin can have much higher clearances during 
RRT because of the absence of tubular resorption which 
would maintain higher concentrations in patients with 
residual renal function [6, 7].
A series of studies from Roger et  al. recently studied 
the effect of the type of RRT, as pharmacokinetic sub-
studies of a clinical trial that compared the same dose of 
RRT, administered as either continuous venovenous hae-
mofiltration (CVVHF) or CVVHDF. The drugs of inter-
est included amikacin [8], ciprofloxacin [9] and linezolid 
[10]. Surprisingly there was no consistent effect of the 
type of CRRT. For the renally cleared amikacin and cipro-
floxacin, CVVHF had a modestly higher mean drug clear-
ance (5.2% and 12.8%, respectively) whereas CVVHDF 
resulted in a higher mean clearance for linezolid (20.5%). 
Recommended dosing regimens for amikacin and line-
zolid were 25 mg/kg 36–48-hourly and 600 mg 12-hourly, 
respectively. Each of these reports, like most RRT phar-
macokinetic studies, observed high pharmacokinetic var-
iability highlighting that comparison of mean parameter 
values or concentrations can be misleading. Therefore, 
understanding the distribution of these values is impor-
tant to understand the range of dosing possibilities for 
any drug–RRT combination.
The effect of the residual renal function of the patient 
on meropenem dosing requirements was investigated 
by Ulldemolins et  al.; the authors found that the vol-
ume of residual diuresis was important with urine out-
puts  greater than 500  mL/day, requiring an additional 
dose per 24-h period or administration by an extended 
infusion [11].
Further exploration of the role of changing the method 
of infusion of beta-lactams was separately performed 
by Shotwell et al. [12] and Jamal et al. [13, 14]. Shotwell 
and colleagues analysed piperacillin concentrations in 
68 CRRT patients. The authors found that only 45% of 
patients achieved their therapeutic target (mid-dosing 
interval concentration  greater than 64  mg/L) with an 
8  g/day dose whereas this increased to 95% with 12  g/
day dosing. The importance of infusion duration of beta-
lactams was emphasised by two RCTs from Jamal et al. of 
meropenem [13] and piperacillin [14]; the authors found 
that administration as a continuous infusion resulted in 
higher achievement of concentration targets than 30-min 
intermittent infusions did. Importantly though, pro-
longed infusions were observed only to be useful for less 
susceptible pathogens, particularly if high doses are used 
empirically (the investigators used 3  g/day meropenem 
and 16 g/day piperacillin).
Another important emerging use of RRT is as an 
adjunctive therapy with aggressive antimicrobial dosing 
in order to achieve pharmacodynamics targets. In a pilot 
study of 15 patients, Brasseur et  al. described the treat-
ment of multidrug-resistant (MDR) Gram-negative sepsis 
with high-dose aminoglycosides and high-flow (greater 
than 45  mL/kg/h) CVVHDF [15]. The use of high-flow 
CRRT allowed the combination of a bactericidal concen-
tration (peak/MIC ratio greater than 8) followed by rapid 
drug removal resulting in a safe trough concentration, in 
turn allowing an earlier subsequent bactericidal dose.
In conclusion, the recent literature relating to phar-
macokinetics in RRT has demonstrated high interpa-
tient variability and that a more consistently accurate 
approach to dosing remains elusive. Clinicians should be 
aware of prescribed and delivered RRT doses as well as 
the patient’s residual renal function in considering dosing 
requirements for patients. Finally, we note the emergence 
of various new compounds in late phase studies, or that 
have been recently licensed, and we strongly recommend 
that appropriate dosing regimens be defined for RRT.
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